CliffBio
biologic

Nemluvio

nemolizumab-ilto

Loss of exclusivityAugust 2036projected — 12-year biologic exclusivity estimate
CompanyGalderma Laboratories, L.P. →View the full company profile on CliffBio

Drug detail

Brand nameNemluvio
Active ingredientnemolizumab-ilto
Strength30MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2024
Marketing statusRx

More from Galderma Laboratories, L.P.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nemluvio patent cliff — loss of exclusivity August 2036 | CliffBio